Idogen AB (“Idogen”) announces today that the company has successfully established a novel method for the preparation of their tolerogenic cell therapy. In January 2019 an evaluation of a number of new potential methods in an improved analysis model was initiated, which makes it possible to assess the tolerogenic effect on human immune cells in the laboratory with improved precision. This extensive work has now been completed with very good results.
Idogen’s tolerogenic cell therapy is based on dendritic cells, a type of white blood cells that plays a central role in the immune defence because they control the behaviour of other immune cells towards endogenous (self) and foreign molecules.
Idogen announced in January 2019 that analyses performed in a scientifically improved evaluation model showed that the company’s technology so far, based on zebularine as an tolerance inducer, did not give the effect that earlier preclinical experiments had indicated. Therefore, a comprehensive systematic evaluation of a number of alternative tolerance inducers was initiated in order to identify a more effective method to generate dendritic cells that educates the body to tolerate drugs, endogenous molecules and cells. This work has led to the establishment of a new method for the development of the company’s cell therapy projects in the areas of hemophilia (IDO 8), kidney transplant (IDO T) and autoimmune diseases (IDO AID). The new method is based on a carefully selected combination of tolerance inducing substances that will replace zebularine.Idogen is now continuing the preparation of the company’s tolerogenic cell therapy based on the new method. The next important sub target is to initiate a clinical study of IDO 8 in hemophilia patients who have developed immunity against their treatment.Based on the positive result from an initial intellectual property assessment, Idogen has started work on compiling patent applications for the new method.”The success of our systematic evaluation work means that we have been able to establish a significantly stronger method for the preparation of our tolerogenic cell therapy. The last few months have been a test of strength for the company’s employees and with the promising results achieved we can now look back on our efforts with pride. We are now continuing the development of our projects at a fast pace”, says Idogen’s CEO, Lars Hedbys. For additional information, please contact:
Lars Hedbys, CEO Idogen ABTel: +46 (0)46-275 63 30E-mail: firstname.lastname@example.orgThis is an English version of an original Swedish press release communicated by Idogen AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply. This constitutes information that Idogen AB is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on 18 June 2019
Idogen (Spotlight Stock Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissue. Idogen’s most advanced product candidate IDO 8 is designed for patients with severe haemophilia A who have developed anti-drug antibodies against their critical treatment with coagulation factor VIII (factor VIII). The company´s second project IDO T is developed to prevent kidney transplant rejection. In a third project, IDO AID, Idogen focuses on the treatment of autoimmune diseases. The treatment is based on the patient’s own cells and is expected to have a favorable safety profile and long-lasting effect. The fact that a short treatment has the potential to yield a long-lasting effect is another great advantage. For more information, visit www.idogen.com